ST Pharm, a leading Contract Development and Manufacturing Organization (CDMO) for oligonucleotide nucleic acids, recently marked a significant milestone with the completion of its 2nd Oligo Building at the Banwol Campus in Ansan, Gyeonggi Province. This pivotal moment not only solidified ST Pharm’s position in the global market but also heralded the launch of their Oligonucleotide CDMO Super-Gap Strategy, aimed at revolutionizing client-centric services in the biotech industry.
The ceremony, held on September 4, was graced by esteemed members of the Dong-A Socio Committee, including Chairman Kang Jungseok, and executives from Dong-A Socio Group. The completion of the 2nd Oligo Building signifies ST Pharm’s commitment to meeting the growing demands of the oligonucleotide nucleic acid CDMO market, particularly from global pharmaceutical companies seeking cutting-edge solutions.
Constructed by Aben General Construction, known for their expertise in cGMP facilities, the 2nd Oligo Building boasts impressive features. Spanning 3,300 pyeong (10,900 square meters) and standing tall at 60 meters with nine floors, this state-of-the-art facility is designed to cater to projects of varying scales. Unlike its predecessor, the building houses small, medium, and large-scale production lines to offer a comprehensive range of services from early clinical stages to commercialization, catering to diverse client needs effectively.
One of the strategic highlights of the 2nd Oligo Building is the inclusion of a “Future area” on the top two floors, allowing for flexibility in accommodating client requests. Moreover, the building is equipped with cutting-edge systems such as an automated Process Control System (PCS), Building Management System (BMS), and Warehouse Management System (WMS) to enhance productivity and operational efficiency.
In line with global ESG standards, ST Pharm has implemented sustainable practices within the new facility, including the reuse of waste heat for heating, innovative distillation systems, and advanced technologies to promote environmental stewardship. This commitment underscores the company’s dedication to responsible and eco-friendly manufacturing processes.
With the completion of the 2nd Oligo Building, ST Pharm is poised to strengthen its core business areas, which include oligonucleotide nucleic acid CDMO, small molecule synthetic drug substance production, and mRNA therapeutic production utilizing proprietary platforms such as Smart Cap and STLNP. CEO Sung Mooje expressed the company’s dedication to customer-centric innovation and a vision to lead as an innovative life-saving entity in the biotech landscape.
The event was attended by key industry figures, including executives from overseas client companies, further emphasizing the significance of this achievement within the biotech community. The collaboration and support from industry leaders reflect the promising future ahead for ST Pharm and its pioneering initiatives in the field.
In conclusion, the completion of ST Pharm’s 2nd Oligo Building stands as a beacon of innovation and progress in the realm of oligonucleotide CDMO. With a strong focus on client needs, operational excellence, and sustainability, ST Pharm is set to redefine industry standards and pave the way for transformative advancements in biotechnology.
Key Takeaways:
- ST Pharm’s 2nd Oligo Building marks a significant advancement in oligonucleotide CDMO capabilities, enhancing client-centric services and operational efficiency.
- The strategic features of the new facility, including diverse production lines and advanced management systems, underscore ST Pharm’s commitment to meeting varied client demands.
- Sustainable practices integrated into the building’s design align with global ESG standards, reflecting ST Pharm’s dedication to responsible manufacturing.
- The completion ceremony, attended by industry leaders and overseas executives, signifies the industry-wide recognition of ST Pharm’s pioneering initiatives and future potential.
- CEO Sung Mooje’s vision for customer-centric innovation positions ST Pharm as a leading force in biotechnology, driving towards life-saving advancements and industry excellence.
Read more on asiae.co.kr